Hotta, Masatoshi http://orcid.org/0000-0001-6790-8804
Sonni, Ida
Benz, Matthias R.
Gafita, Andrei
Bahri, Shadfar
Shuch, Brian M.
Yu, Run
Liu, Sandy Ting
Czernin, Johannes
Calais, Jeremie
Funding for this research was provided by:
Society of Nuclear Medicine and Molecular Imaging (ERF- SNMMI (2019–2021 Molecular Imaging Research Grant for Junior Academic Faculty))
Article History
Received: 5 March 2021
Accepted: 18 April 2021
First Online: 29 April 2021
Declarations
:
: Johannes Czernin is a founder and board member, and holds equity in Sofie Biosciences and Trethera Therapeutics. Intellectual property patented by the University of California is licensed to Sofie Biosciences and Trethera Therapeutics. Johannes Czernin serves on the medical advisory board of Actinium and is a member of the VISION trial steering committee, a clinical trial sponsored by Endocyte. Johannes Czernin is the recipient of a grant from the US Department of Energy (DESC0012353), from the Prostate Cancer Foundation (2017 and 2019 Challenge Awards, 17CHAL02 19CHAL02), and from the Johnson Comprehensive Cancer Center NIHNCI Cancer Center Support Grant (P30 CA016042). Jeremie Calais is the recipient of grants from the ERF-SNMMI (2019–2021 Molecular Imaging Research Grant for Junior Academic Faculty), the Philippe Foundation Inc. (NY, USA), and the ARC Foundation (France) (International Mobility Award SAE20160604150). Jeremie Calais is a consultant for Blue Earth Diagnostics, Curium Pharma, GE Healthcare, Janssen Pharmaceuticals, Progenics Radiopharmaceuticals, Radiomedix, and Telix Pharmaceuticals, outside of the submitted work. All other co-authors have no conflict of interest.
: All procedures performed in this study were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Written and oral informed consent for participation and publication was provided by the patient involved in this study.